| Warning:  Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
 
 Deprecated:  str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
 
  
 Warning:  Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 
 Warning:  Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
 Warning:  file_get_contents(http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=17088581&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
 in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 445
 
   English Wikipedia
 
 Nephropedia Template TP (
 
 Twit Text
 
 
 DeepDyve
 Pubget Overpricing
 | lüll   
 
 Narrative review: protein degradation and human diseases: the ubiquitin  connection Reinstein E; Ciechanover AAnn Intern Med  2006[Nov]; 145 (9): 676-84Between the 1950s and 1980s, many scientists focused on the process by which the  genetic code is translated into proteome. However, little attention was devoted  to the mechanism responsible for protein degradation. When researchers discovered  the organelle lysosome, they assumed that cellular proteins were degraded within  it. However, several independent lines of evidence strongly suggested that  intracellular proteolysis was largely nonlysosomal. The discovery of the  ubiquitin proteasome system (UPS) resolved this enigma. It is now recognized that  degradation of intracellular proteins by the UPS is involved in the regulation of  a broad array of cellular processes, including cell-cycle division; DNA repair,  growth, and differentiation; quality control; and regulation of membrane  receptors and ion channels. Not surprisingly, aberrations in the system have been  implicated in the pathogenesis of numerous human diseases, and it seems that  pharmacologic manipulation of the UPS might alter the outcome of many diseases,  especially malignant conditions and possibly neurodegenerative and chronic  inflammatory diseases. These findings have led to increasing efforts to develop  mechanism-based drugs that modulate UPS activity, one of which is already on the  market. In the near future, one can expect to see the development of new, potent,  and highly specific drugs that target the degradation pathways of a single or a  few proteins without affecting other proteins.|Antineoplastic Agents/pharmacology[MESH]|Biodegradation, Environmental[MESH]|Dietary Proteins/metabolism[MESH]|Humans[MESH]|Neoplasms/*metabolism[MESH]|Neurodegenerative Diseases/*metabolism[MESH]|Proteasome Endopeptidase Complex/*metabolism[MESH]|Proteasome Inhibitors[MESH]|Proteins/*metabolism[MESH]|Ubiquitin/antagonists & inhibitors/*metabolism[MESH]|Virus Physiological Phenomena[MESH]
 |